• Distinguished Professor, Zhengzhou University, Zhengzhou, China

Foreign Academician, Russian Academy of Natural Sciences;

Chair, Committee of Hypoxia Cancer Biology, Chinese Anti-Cancer Association.

Henan Provincial High-Level Talent

Former Professor and Vice Chair, Department of Pathology; and Director, Center of Environmental Exposure, Thomas Jefferson University, Philadelphia, USA

Former Endowed Chair Professor of Cancer Research, Professor of University of Iowa, Iowa City, USA

• Associate Editor, Genes & Diseases; editorial boards of The FEBS Journal, Plos One and Frontiers in Bioscience.
• Bing-Hua Jiang initially identified and cloned hypoxia-inducible factor-1 (HIF-1), characterized HIF-1 functional domains and oxygen-sensing regulation as well as its role in cancer and ischemic disease, a discovery that laid the foundation for the 2019 Nobel Prize in Physiology or Medicine. He also pioneered the identification of the PI3K/AKT pathway’s role in tumor angiogenesis and cancer progression, establishing a molecular framework now widely adopted in cancer biology and therapy research. He obtained many NIH R01 grants and published more than 230 articles with more than 45,000 citations (H-index 91). He has had a transformative impact on hypoxia, cell signaling, angiogenesis, and cancer therapeutic resistance, and obtained several prestigious Awards including The First Prize of the National Science and Technology Progress Award and American Cancer Society Research Scholar Award.

CBE, MD, PhD, FRCPath, FMedSci
Medical Director, NIHR Clinical Research Network; Professor of Molecular Oncology
Director of the Barts Cancer Institute 2003-2024
Foreign Academician of the Chinese Academy of Engineering
Centre Lead, Group Leader

• Tenured Professor, St. John’s University, USA

Director, Laboratory of Cancer Pharmacology, College of Pharmacy

Former Director, Institute of Biotechnology (2016–2024)

Distinguished/Visiting Professor at Sun Yat-sen University, Sichuan University, Beijing University of Chinese Medicine, and others

• Editor-in-Chief of Drug Resistance Updates and Recent Patents on Anticancer Drug Discovery; Specialty Chief Editor of the Cancer Cell Signaling section and Frontiers in Oncology; Senior Editor of Biomolecules and Biomedicine.
• Professor Zhe-Sheng Chen is a world-renowned expert in cancer multidrug resistance (MDR) and its reversal. He is also on the editorial board of over 30 journals, including Cancer Letters, MedComm, and Chinese Medicine, and acts as a reviewer for more than 200 international journals, including Science and Nature As a globally recognized grant reviewer, he has evaluated proposals for NIH (USA), NSFC (China), and funding agencies in Canada, France, the Netherlands, and other countries.His research has significantly advanced our understanding of MDR mechanisms and the development of therapeutic reversal agents. He has published over 500 SCI papers in high-impact journals such as Chemical Society Reviews, Nature Communications, Advanced Materials, and Molecular Cancer, with more than 36,000 citations and an H-index of 93. He holds 7 invention patents (from the US and China) and has authored or edited 15 English books. His accolades include the AACR Young Scientist Award, the St. John’s University Achievement Award, and 14 Outstanding Faculty Awards, as well as recognition in the “Lifetime Scientific Influence Ranking” and the “2023 Global Scientific Influence Ranking.”

• Dean, Institute of Translational Medicine, Zhejiang University

Deputy Dean, School of Medicine, Zhejiang University

Changjiang Scholar Chair Professor (Ministry of Education, China)

Chief Scientist, National Center for Fundamental Science

Chief Scientist, National Key R&D Program of China

Former Ruby E. Rutherford Distinguished Endowed Professor, MD Anderson Cancer Center

Founding Director, Cancer Metabolism Program, MD Anderson Cancer Center

Foreign Member, Academia Europaea (2021)

Chinese Medical Science and Technology Award – International Scientific and Technological Cooperation Award (2022)

• Editor-in-Chief of Visualized Cancer Medicine; Deputy Editor-in-Chief of Journal of National Cancer Center; Editorial Board Member for journals including Cell Research, The Journal of Biological Chemistry, among others.
• Zhi-min Lu published more than 150 research articles in top peer-reviewed journals, and about 70 of these papers, as a corresponding author, were published in Cell, Nature, Nature Cell Biology, Cancer Cell, Nature Cancer, Cancer Discovery, Cell Metabolism, Molecular Cell, Nature Metabolism, Nature Structural and Molecular Biology, Science Advances, Nature Reviews Molecular Cell Biology, Nature Reviews Cancer, Annual Review of Biochemistry, Trends in Cell Biology, Trends in Cancer, and Trends in Biochemical Sciences.

• Professor, Department of Biomedical Sciences, College of Biomedicine, City University of Hong Kong.

Panel member of The Biology and Medicine of RGC/NSFC (Joint Research Scheme, JRS) since 2023.

• Editorial Board Members of Signal Transduction and Target Therapy, MedComm and American Journal of Cancer Research; Guest Editor of Pathogens, Biomedicines and Pharmaceutics; Associate editor of Genes & Diseases
• Ming-Liang HE has been focusing on the molecular mechanisms of human diseases caused by virus infections (including human cancers and acute infectious diseases) and target-specific antiviral/antitumor drug development. He was among the earliest scientists studying the severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV-1) in 2003. He has published near 200 research/review articles in high profile research journals (such as Nat Chem, JAMA, STTT, PNAS, Cancer Res., Adv. Mater., Adv. Sci., Adv. Funct. Mater., Nat. Cummun., Biomaterials, J. Infect., etc) with over 11,000 citations and H-index of 63. He has granted quite a few US and Chinese patents.

• Professor, Sun Yat-sen University Cancer Center

Principal Investigator, State Key Laboratory of Oncology in South China

Director, Center for Cancer Metabolism and Intervention Research, Sun Yat-sen University Cancer Center

Director, Platform for Metabolomics Technology, Sun Yat-sen University

• Executive Editor-in-Chief, Cancer Communications; Associate Editor, Cancer & Metabolism
• Peng Huang obtained his medical degree from Sun Yat-sen University School of Medicine and his PhD Degree from the University of Texas Health Sciences Center in Houston. He was an Ashbel Smith Endowed Professor at the University of Texas MD Anderson Cancer Center before he joined Sun Yat-sen University Cancer Center. His research interests are in the areas of cancer metabolism, ROS/redox signaling, mitochondrial biology, and therapeutic strategies/drugs that target the abnormalities in cancer metabolism. His research has led to a series of publications in Nature, Cell, Nature Medicine, Cancer Cell, Nature Cell Biology, Nature Reviews Drug Discovery, and other professional journals. He has been recognized as a highly cited scholar for the past seven consecutive years.

• Chair Professor, Shanghai Jiao Tong University

Director, Institute of Cell and Gene Therapy

Former Ronald L. Whisler Endowed Chair Professor, The Ohio State University

Distinguished Expert, National High-Level Overseas Talent Program

NSFC Outstanding Young Investigator (Overseas)

President, Basic Immunology Branch, Asia-Pacific Biomedical Immunology Association

Chair, Biological Therapy Branch, Chinese Health Management Association

President, Songjiang Association for Science and Technology, Shanghai

• Honorary Editor-in-Chief of iCELL. Editor-in-Chief of Am J Clin Exp Immunol; Associate Editor of MedComm and Front Immunol; Editorial Board Member of Cytokine Growth Factor Rev, Cell Mol Immunol, Mol Ther, J Mol Cell Biology, Theranostics, and View.
• Professor Song-Guo Zheng is a pioneering founder in the discovery and nomenclature of inducible regulatory T cells (iTregs), with long-standing expertise in T cell regulation, autoimmunity, and tumor immunology. He has published over 230 SCI papers, ( 20 ≤ IF ≤ 50: 18 papers, 10 ≤ IF ≤20: 49 papers), accumulating over 20,000 citations and an H-index exceeding 80. He has led multiple NIH and national key research projects and authored four English monographs. His accolades include the NIH STAR Award, ACR Distinguished Investigator Award, Dona Immunologist Award, Freda Newton Memorial Scholar Award, and Edmund Dubois Award, among more than 20 international honors.

Biography (<500 words) – please feel free to cut short for your advertisement

Evandro F. Fang is an Associate Professor of Molecular Gerontology at the

University of Oslo (UiO) and the Akershus University Hospital, Norway, and his

group are working on the molecular mechanisms of human ageing and age-

predisposed neurodegeneration (https://evandrofanglab.com/). More

specifically, the Fang laboratory is focusing on the molecular mechanisms

behind how cells clear their damaged and aged mitochondria, a process termed

“mitophagy”, as well as the roles of the NAD+-mitophagy/autophagy axis in

healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and

health and decreases in ageing and AD. Dr Fang is fascinated with and actively

engaged in moving his laboratory findings to translational applications and is

involved in 5 NAD+-based clinical trials, with the overarching goal of

establishing novel and safe biological approaches to promote longer and

healthier human lives.

He has published over 100 papers in international peer-reviewed journals

including papers in Cell, Cell Metabolism, Nature Reviews MCB, Nature

Neuroscience, Nature Ageing, Nature Biomedical Engineering, and Lancet

Healthy Longevity. He routinely reviews grants for more than 30 leading

foundations, including European Research Council (ERC, EU), Medical

Research Council (MRC, UK), and AFAR (USA). He has been associate Editor-

in-Chief (Deputy Editor) of 4 leading ageing journals, including Ageing

Research Reviews, Mechanisms of Ageing and Development, npj Ageing, and

Journal of Gerontology: Biological Section. He has received several awards

including the Butler-Williams Scholar on Aging 2016 by NIA (USA), the

'Scientific Award to Young Scientist in the Natural Sciences for 2020 by The

Royal Norwegian Society of Sciences and Letters (Norway), and the 2023

Norwegian National Dementia research award of the National Association for

Public Health presented by H.M. King Harald V of Norway.

After finishing his PhD at the Chinese University of Hong Kong, he had a 6-year

postdoc training with Prof. Vilhelm Bohr on molecular gerontology and Prof.

Mark Mattson on neuronal resilience in Alzheimer’s disease at the National

Institute on Ageing, Baltimore. He opened his lab in Oslo in the fall of 2017. He

is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing

network (NO-Age, www.noage100.com), the Norwegian National anti-

Alzheimer’s disease Network (NO-AD, www.noad100.com), and the Hong

Kong-Nordic Research Network. He sits in the expert roundtable on aging

research for the United Nation’s Scientific Advisory Board.

• Tenured Professor and University Endowed Chair,
• Department of Pathology, University of Iowa, USA
• He obtained PhD in Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa, United States
• He served for more than 10 years at NIH study sections; as Editorial members of several international journals
•  

Professor Jia Luo is a world-renowned expert in cancer and neuroscience. His laboratory is to focus on the following research field:  (1) Alcohol exposure during development results in fetal alcohol spectrum disorders (FASD) and induces profound damages to the central nervous system (CNS). He is interested in elucidating cellular/molecular mechanisms underlying alcohol-induced damage to the developing brain. Particularly he is interested in the interaction among oxidative stress, endoplasmic reticulum (ER) stress and autophagy and how the interaction contributes to alcohol-induced CNS damage. Chronic and heavy alcohol abuse also causes neurodegeneration and thiamine deficiency (TD). He is interested in the interaction between TD and alcohol abuse in the context of neurodegeneration and behavioral deficits. (2) Alcohol is a tumor promoter and enhances the progression of mammary tumor. He is interested in elucidating cellular/molecular mechanisms underlying alcohol-promoted tumor progression, particularly the metastasis of breast cancer cells. (3) Alcohol abuse is the major risk factor for pancreatitis. He is interested in elucidating the role of ER stress in alcohol-promoted pancreatitis.

• Director, Professor, and Senior Investigator, Institute of Cancer Prevention and Treatment, Guangdong-Hong Kong-Macao Greater Bay Area Institute of Precision Medicine (Guangzhou)

Professor Emeritus, Duke University School of Medicine

Tenured Professor, Duke University School of Medicine

Tenured and Endowed Professor, The University of Texas MD Anderson Cancer Center

Changjiang (Yangtze River) Chair Professor, Ministry of Education of China

• Founding Editor-in-Chief of Cancer Medicine; Executive Editor of Journal of Biomedical Research
• Professor Qingyi Wei has made pioneering contributions to the fields of DNA damage repair, cell death, genomics, and the molecular epidemiology of cancer development and prognosis. He has been devoted to elucidating cancer mechanisms and advancing precision prevention strategies. He has published over 600 SCI papers, with more than 46,700 citations and an h-index of 106, demonstrating his far-reaching academic impact.

• Senior Principal Investigator, Senior Principal Scientist，Bioinformatics Institute (BII), ASTAR

Head, Intelligent Digital and Molecular Pathology (iDMP) Lab

Adjunct Assoc. Professor, Department of Pathology and Department of Biochemistry, YLL School of Medicine, National University of Singapore (NUS)

Adjunct Assoc. Professor, School of Biological Sciences, Nanyang Technological University (NTU)

Co-founder, A!maginostic Pte. Ltd.

• Weimiao YU has been contributing to the fields of computational pathology and biomedical AI, with a multidisciplinary background that began with his early research on collective cell migration and tissue morphogenesis. Building on this foundation, he has expanded his focus to the integration of artificial intelligence in digital pathology and multiplex immunofluorescence (mIF) imaging. He has been leading in the development of AI-assisted platforms such as A!Prostate, A!HistoClouds and A!Prostate etc., and currently leads the AIDP Programme—an SGD 16.4 million national initiative to build annotated pathology databases, diagnostic tools and large scale adoption of AI solutions in clinical practice. Over the 20 years, he has helped secure research funding exceeding SGD 28 million and has fostered collaborations across academic, clinical, and industry domains. Committed to bridging research and practical application, Prof. Yu’s work aims to support diagnostic innovation and translational progress in oncology.